Azitra has also granted the underwriters a 45-day option to purchase up to an additional 2.5 million shares of common stock to cover over-allotments at the public offering price.
The company intends to use the net proceeds for clinical trials and product development, research and development, clinical manufacturing as well as for working capital and other general corporate purposes.
The offering is expected to close on February 16, 2024.
